Teradata delivered one of the more conflicted setups in the software space this week: short sellers covered aggressively while every senior insider reaching for the sell button.
The dominant move in the data this week is the short squeeze unwind. Short interest collapsed 24% over the week to 13.6% of the float — down from roughly 16.6 million shares to 12.7 million in a single session on June 9. That is still a high absolute level, but the direction of travel is decisive. The ORTEX short score has dropped from 68.4 on June 5 to 64.9 on June 9, reflecting that easing pressure. Borrow costs remain almost irrelevant at 0.52%, and availability is comfortably in normal territory at 308% — meaning the lending pool is nowhere near stressed. The sharp covering happened against a backdrop of plenty of supply, which makes it a deliberate positioning decision rather than a forced squeeze.
Options positioning has nudged slightly more cautious alongside the price retreat, but not dramatically so. The put/call ratio has drifted to 0.23 from a 20-day average of 0.20 — around 1.4 standard deviations above the mean, edging toward the more defensive end of recent history. The 52-week range for the PCR runs from 0.05 to 0.42, so the current reading is nowhere near alarm territory. Options traders are adding a modest layer of protection into the stock's 8.3% weekly decline to $33.47, but nothing about the options market screams panic.
The Street's view of TDC is deeply divided, and the analyst activity has not resolved that tension. Citizens reiterated a Market Outperform with a $49 target as recently as June 10 — a reading that implies 46% upside from current levels and sits conspicuously above the $33.44 consensus mean. UBS held Neutral and trimmed to $34 following the May earnings print. Barclays maintained Underweight with a $28 target. Citigroup kept its Buy but cut to $38 from $42 in late April. The bull case rests on AI workload monetisation through the Vantage and ClearScape platform and a structurally improving margin profile. The bear case is blunter: cloud ARR growth has consistently disappointed, competition from both legacy and cloud-native analytics vendors is intensifying, and forward earnings expectations are declining sharply — the 12-month forward EPS growth rank sits in the bottom 5th percentile. The EV/EBITDA multiple of 6.9x has compressed slightly over the past 30 days, but with an EPS surprise factor score in the 95th percentile, the company has at least been beating low expectations consistently. The short score rank of 6 out of 100 is worth noting — it flags that while shorts are covering now, the overall ORTEX scoring framework still places TDC in the most-shorted decile of the universe.
The insider picture adds a genuinely uncomfortable layer to the bull case. Every recorded transaction over the past 90 days has been a sale. The CFO sold 13,355 shares in May. The President and CEO sold 20,000 shares on May 12 at $31.71. Multiple C-suite officers sold in late May and early June. The net insider position over 90 days is technically positive at 253,026 shares, but that reflects option grants rather than open-market buying — the cash transactions are uniformly pointing one way. It is rare to see a management team selling this consistently through a period when they are publicly talking up AI optionality and platform transformation. Close correlated peers CDNS and GEN were both weaker on the week, down 6% and 9% respectively, so TDC's 8% decline was broadly in line with software sector weakness rather than company-specific news.
The next earnings event is August 3. Between now and then, the key variable is whether the short covering of the past week marks a genuine re-rating or simply a positioning reset after an extended bearish run — the insider selling pattern, the sub-$34 consensus target, and the Barclays $28 floor provide the parameters worth watching as that date approaches.
See the live data behind this article on ORTEX.
Open TDC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
